Analysts' profit expectations for the group have risen sharply since
the start of the year, while estimates for most of the other nine
Standard & Poor's 500 macro sectors have fallen, according to
Thomson Reuters data.
The jump in forecasts has come in the past two months, thanks
largely to rising estimates for biotechnology companies such as
Gilead <GILD.O>, and for insurers, including Aetna <AET.N>.
It provides some early evidence that President Barack Obama's
signature healthcare overhaul could be a long-term source of profit
growth for managed care providers.
"Now you're actually seeing real numbers grow and that population
start to take off," said Betsy Pecor, portfolio manager at Eagle
Asset Management, based in St. Petersburg, Florida. Companies "are
actually seeing that growth."
About 8 million people have signed up for the plans, which are
provided by commercial subscribers and come with income-based
government subsidies, above the 2 million who had enrolled by
Aetna and other insurers have said they lost money on the plans this
year, but insurers are heading into new markets for 2015 to add
Many healthcare companies are better able to manage Obamacare now
than they were last year, Pecor said.
Profit estimates for healthcare companies for 2014 have jumped from
up 8.3 percent at the start of January to up 12.2 percent now, one
of just a few sectors with a 2014 earnings outlook that exceeds
profit-growth forecasts at the start of the year, Thomson Reuters
Earnings growth estimates for the whole S&P 500 this year have gone
down slightly in that period, from 10.8 percent in January to 9.1
The upward revision is also the most of any sector except utilities,
where estimates reflect a blow-out first quarter courtesy of home
heating needs during the cold winter in North America. By contrast,
the revisions to the health sector earnings reflect rising
expectations for the second quarter and beyond.
The question for investors is whether the improving outlook is
already reflected in stock prices.
The healthcare sector <.SPXHC> jumped 39 percent in 2013, more than
any other sector except consumer discretionaries <.SPLRCD>.
Healthcare is up 10.2 percent so far for 2014, outpacing the 6
percent rise for the wider S&P 500, but its advance has shown signs
of slowing in the last month or so.
"You have more people using healthcare at these higher rates, and
that's going to get you earnings, but my question is for how long,"
said Kim Forrest, senior equity research analyst, Fort Pitt Capital
Group in Pittsburgh. "It's really unclear at this point how much
money this is and how long it can be sustained."
To be sure, valuations for the healthcare sector are relatively
high. The price-to-earnings multiple for the sector is at 16.9, down
from 17.3 at the start of the year. That compares with the S&P 500's
earnings multiple of 16.0, which is up from about 15.1 at the start
of 2014, Thomson Reuters data showed.
There may still be pockets of value, especially in the health
industry groups that have seen the greatest growth in earnings
forecasts: biotech and insurance. Biotech's P/E ratio is 16.8
compared with 24.5 at the start of the year, while the average P/E
ratio for the five managed care companies in the S&P 500 is 13.6, up
from 12.4 at the beginning of 2014.
[to top of second column]
Phil Orlando, chief equity market strategist at Federated Investors
in New York, said his firm rotated money out of the high-growth
biotech names and into less volatile names in the healthcare sector
in March, but he still likes biotech.
"There will come a point in the cycle, maybe later this year, that
we put some money back into these biotechnology names."
Biotechnology companies, which were top victims in the sell-off of
so-called momentum stocks earlier this year, are the biggest
contributors to the gain.
Biotechs are benefiting from pricing power, as more of their
blockbuster drugs come on the market, analysts said. The U.S. Food
and Drug Administration approved 39 drugs last year, the most of any
year except 1996.
"They're all in the midst of launching or have launched new products
that are head and shoulders above the existing products out there,
and they're getting the pricing and the demand," said David Heupel,
senior healthcare analyst at Thrivent Investment Management, in
In the past 90 days, 25 analysts raised their profit expectations
for the full year on Gilead, the maker of the market-leading
hepatitis C treatment, Sovaldi, with a mean change of 65 percent
higher. None revised expectations lower, Thomson Reuters StarMine
Sovaldi's $84,000 price tag for a 12-week treatment is so high,
however, that it has come under fire from insurers, who are pushing
Gilead's rivals to offer lower prices when their hepatitis C
medicines go on the market.
For Alexion Pharmaceuticals <ALXN.O>, 18 analysts raised their
profit estimates in the past 90 days, with a mean change of 9.8
percent higher, while none revised them lower.
Among insurers, 12 analysts raised their profit expectations over
the past 90 days for Aetna's earnings, with a mean change of 2.2
percent higher, and just one revised them lower. For Cigna <CI.N>,
15 analysts increased their profit estimates in the period, with a
mean of 1.8 percent higher, compared with one revising them down,
according to the StarMine data.
The number of analysts who raised their earnings expectations for
the healthcare sector as a whole in the past 90 days is 416 compared
with 391 who lowered them over the same period, with a mean change
of 3.1 percent higher.
(Reporting by Caroline Valetkevitch, editing by John Pickering)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.